Ofatumumab in poor-prognosis chronic lymphocytic leukemia: A phase IV, non-interventional, observational study from the European research initiative on chronic lymphocytic leukemia

Haematologica

Volumn 100, Issue 4, 2015, Pages 511-516

  Moreno, Carol ^a   Montillo, Marco ^b   Panayiotidis, Panayiotis ^c   Dimou, Maria ^c   Bloor, Adrian ^d   Dupuis, Jehan ^e   Schuh, Anna ^f   Norin, Stefan ^g   Geisler, Christian ^h   Hillmen, Peter ⁱ   Doubek, Michael ^j   Trněný, Marek ^k   Obrtlikova, Petra ^k   Laurenti, Luca ^l   Stilgenbauer, Stephan ^m   Smolej, Lukas ⁿ   Ghia, Paolo ^o   Cymbalista, Florence ^p   Jaeger, Ulrich ^q   Stamatopoulos, Kostas ^r   Stavroyianni, Niki ^r   Carrington, Patrick ^s   Zouabi, Hamadi ^t   Leblond, Veronique ^t   Gomez Garcia, Juan C ^u   Rubio, Martin ^u   Marasca, Roberto ^v   Musuraca, Gerardo ^w   Rigacci, Luigi ^x   Farina, Lucia ^y   Paolini, Rossella ^z   Pospisilova, Sarka ^j   Kimby, Eva ^g   Bradley, Colm ^aa   Montserrat, Emili ^ab   more..

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c UNIVERSITY OF ATHENS   (Greece)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e HENRI MONDOR HOSPITAL   (France)

^f CHURCHILL HOSPITAL   (United Kingdom)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h Rigshospitalet   (Denmark)

ⁱ ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^j UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^k CHARLES UNIVERSITY   (Czech Republic)

^l CATHOLIC UNIVERSITY   (Italy)

^m UNIVERSITY OF ULM   (Germany)

ⁿ UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^o VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^p AVICENNE HOSPITAL   (France)

^q MEDICAL UNIVERSITY OF VIENNA   (Austria)

^r G PAPANICOLAOU HOSPITAL   (Greece)

^s TRAFFORD GENERAL HOSPITAL   (United Kingdom)

^t PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^u HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^v UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^w DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^x CAREGGI UNIVERSITY HOSPITAL   (Italy)

^y NATIONAL CANCER INSTITUTE   (Italy)

^z Servizio di Medicina Nucleare   (Italy)

^aa UNIVERSITY OF GLASGOW   (United Kingdom)

^ab HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CHLORAMBUCIL; CORTICOSTEROID; ERYTHROPOIETIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; OFATUMUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CHRONIC LYMPHATIC LEUKEMIA; COUGHING; DYSPNEA; FATIGUE; FEMALE; FEVER; HUMAN; INFECTION; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NEOPLASM; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PHASE 4 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VERY ELDERLY; CLINICAL TRIAL; DRUG ADMINISTRATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MORTALITY; PHASE 4 CLINICAL TRIAL; REMISSION; RETREATMENT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; REMISSION INDUCTION; RETREATMENT; TREATMENT OUTCOME;

EID: 84926299526     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.118158     Document Type: Article

References (25)

1. Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005; 23 (18):4079-4088.
2. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376 (9747):1164-1174.
3. Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Björkholm M, Landgren O. Improved survival in chronic lymphocytic leukemia in the past decade: a populationbased study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica. 2009;94(9):1259-1265.
4. Danese MD, Griffiths RI, Gleeson M, et al. An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood. 2011;117(13):3505-3513.
5. Delgado J, Ghita G, Bumann T, et al. Rituximab-based chemoimmunotherapy prolongs survival of patients with chronic lymphocytic leukemia independently of the time of administration. Clin Lymphoma Myeloma Leuk. 2014;14(1):73-79.
6. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104(6):1793-1800.
7. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177 (1):362-371.
8. Beum PV, Lindorfer MA, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol. 2008;181(1):822-832.
9. Bologna L, Gotti E, Da Roit F, et al. Ofatumumab is more effective than rituximab in B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol. 2013;190 (1):231-239.
10. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as a single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leucemia. J Clin Oncol. 2010;28(10):1749-1755.
11. Lemery SJ, Zhang J, Rothmann MD, et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res. 2010;16 (17):4331-4338.
12. Gravanis I, Ersboll J, Skovlund E, Abadie E, Marty M, Pignatti F. The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use. Oncologist. 2010;15(12):1335-1343.
13. Muller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H. Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In “WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues”, IARC, Lyon 2008, pp. 180-182.
14. Hallek M, Cheson BD, Catovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(9):4446-4556.
15. Chowdhury O, Varghese A, Pattison J, et al. Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme. Br J Haematol. 2011;155(4): 509-533.
16. International Workshop on Chronic Lymphocytic Leukemia. Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. Ann Intern Med. 1989;110(3):236-238.
17. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111(3):1094-1100.
18. Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011;118(19): 5126-5129.
19. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20): 4834-4840.
20. Byrd JC, Brown JR, O’Bien S, et al. Ibrutinib vs. ofatumumab in previously treated chronic lymphocytic leukemia. N Engl J Med. 2014;371(3):213-223.
21. Wierda WG, Kipps TJ, Dürig J, et al. Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011;117(24):6450-6458.
22. Offner F, Panagiotidis P, Afanasyev B, et al. Ofatumumab and bendamustine combination therapy in patients with untreated and relapsed chronic lymphocytic leukemia: initial results of the phase II study OMB115991. XV iwCLL Abstracts 2013 4.29
23. Shanafelt T, Lanasa MC, Call TG, et al. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia. Cancer. 2013;119(21): 3788-3796.
24. Ujjani C, Ramzi P, Gehan E, Wang H, Wang Y, Cheson BD. Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma. 2014;6:1-6. [Epub ahead of print]
25. Hillmen P, Robak T, Janssens A, et al. Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia: results of the phase III study Complement 1 (OMB110911). Blood. 2013;122(21) Abstract 528.